References
- Starr P. A. J., McDonald A. Oculo-cutaneous aspects of rosacea. Proc. Roy. Soc. Med. 1969; 62: 9–111. Starr P. A. J., McDonald A. Oculo-cutaneous aspects of rosacea. Proc. Roy. Soc. Med. 1969; 62: 9–11
- Gamborg Nielsen P. Treatment of rosacea with 1% Metronidazole Cream. Brit. J. Dermatol. 1983; 108: 327–3322. Gamborg Nielsen P. Treatment of rosacea with 1% Metronidazole Cream. Brit. J. Dermatol. 1983; 108: 327–332
- Bleicher P. A., Charles J. J., Sober A. J. Topical metronidazole therapy for Rosace. Arch. Dematol. 1987; 123: 59–613. Bleicher P. A., Charles J. J., Sober A. J. Topical metronidazole therapy for Rosace. Arch. Dematol. 1987; 123: 59–61
- Bannatyne R. M., Harnett N. H. Metronidazole and acne. Acta Dermatol. Venerol. 1976; 56: 307–3084. Bannatyne R. M., Harnett N. H. Metronidazole and acne. Acta Dermatol. Venerol. 1976; 56: 307–308
- Chow A. W., Patten V., Guze L. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore-forming Gram-positive bacilli. J. Infect. Dis. 1975; 131: 182–1865. Chow A. W., Patten V., Guze L. Susceptibility of anaerobic bacteria to metronidazole: relative resistance of non-spore-forming Gram-positive bacilli. J. Infect. Dis. 1975; 131: 182–186
- Leydon J. L. Therapy for acne vulgaris. New Eng. J. Med. 1997; 336: 1156–11626. Leydon J. L. Therapy for acne vulgaris. New Eng. J. Med. 1997; 336: 1156–1162
- Shanker S., Munro R. Sensitivity of Gardnerella vaginalis to metabolites of metronidazole and tinidazole. Lancet 1982; 1: 1677. Shanker S., Munro R. Sensitivity of Gardnerella vaginalis to metabolites of metronidazole and tinidazole. Lancet 1982; 1: 167
- Bannatyne R. M., Jackowski J., Karmali M. A. Susceptibility of Campylobacter species to metronidazole, its bioactive metabolites and tinidazole. Infect. 1987; 15: 457–4588. Bannatyne R. M., Jackowski J., Karmali M. A. Susceptibility of Campylobacter species to metronidazole, its bioactive metabolites and tinidazole. Infect. 1987; 15: 457–458
- Symposium New findings on the antibacterial interactions between cefotaxime and desacetylcefotaxime. Diag. Microbiol. Infect. Dis. 1989; 12: 23–1219. Symposium New findings on the antibacterial interactions between cefotaxime and desacetylcefotaxime. Diag. Microbiol. Infect. Dis. 1989; 12: 23–121
- Jorgensen J. H., Maher L. A., Howell A. W. Activity of clarithromycin and its principal human metabolite against. Haemophilus influenzae. Antimic. Agents Chemother. 1991; 35: 1524–152610. Jorgensen J. H., Maher L. A., Howell A. W. Activity of clarithromycin and its principal human metabolite against. Haemophilus influenzae. Antimic. Agents Chemother. 1991; 35: 1524–1526
- Lau A. H., Lam N. P., Pisatelli S. C., Wilkes L., Danziger L. H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Phamacokin. 1992; 23: 523–53111. Lau A. H., Lam N. P., Pisatelli S. C., Wilkes L., Danziger L. H. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Phamacokin. 1992; 23: 523–531